Axogen, Inc. - Common Stock (NQ:AXGN)

Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair

October 01, 2026

Axogen (NASDAQ:AXGN) Shares Slide After Q2 Earnings Miss Overshadows Revenue Beat and Raised Guidance ↗

Performance

52-Week Range 31.6% below 52-week high

36.17

15.2752W Low 52.9152W High

1 Week 3.3% below 1-week high

35.441W Low 37.401W High

Axogen, Inc. - Common Stock (AXGN) traded between $15.27 and $52.91 over the past 52 weeks and last traded at $36.17, 31.6% below its 52-week high. Over the past week it ranged between $35.44 and $37.40.

Past 12 Months

+0.4%

-17.4%

-6.7%

+5.0%

+16.7%

+132.0%

1W +$0.13

1M -$7.61

3M -$2.60

6M +$1.71

YTD +$5.17

1Y +$20.58

AXGN was +132.0% over the past year, +5.0% over six months, +16.7% year to date, +0.4% in the last week.

12 Months vs Market

AXGN

+132.0%

DIA

+12.1%

SPY

+17.3%

QQQ

+23.5%

IWM

+13.2%

Over the past 12 months AXGN returned +132.0% versus DIA (Dow) +12.1%, SPY (S&P 500) +17.3%, QQQ (Nasdaq 100) +23.5% and IWM (Russell 2000) +13.2%.

Volume & Liquidity 1.74× 3-mo avg

Today 2,136,618 3-mo avg 1.2M

1.5M

1.2M

YTD

1.2M

1.1M

AXGN most recently traded 2,136,618 shares against a 3-month average daily volume of 1.2M.

More News

3 Emerging Biotech Stocks With Significant Upside Potential ↗

September 30, 2026

Via MarketBeat

July 29, 2026

Via Chartmill

Axogen Inc. (NASDAQ:AXGN) Achieves a Perfect Technical Score and Strong Fundamental Growth ↗

June 20, 2026

Via Chartmill

Axogen Inc (NASDAQ:AXGN) Rallies on Q1 Revenue Beat and Raised 2026 Guidance ↗

April 28, 2026

Via Chartmill

Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock

September 10, 2026

Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies

September 10, 2026

Axogen, Inc. to Participate in the 24th Annual Morgan Stanley Global Healthcare Conference

September 01, 2026

Axogen (AXGN) Q2 2026 Earnings Call Transcript ↗

August 07, 2026

Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It

August 11, 2026

From Biotech Insider

AxoGen Q2 Earnings Call Highlights ↗

July 29, 2026

Via MarketBeat

Axogen, Inc. Reports Second Quarter 2026 Financial Results

July 29, 2026

Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026

July 15, 2026

The Newest Name on Nasdaq Wants to Help the Body Rebuild Itself

May 22, 2026

From Energy Metal News

TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues

AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam ↗

May 14, 2026

Via MarketBeat

April 30, 2026

From TELA Bio, Inc.

Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference

April 30, 2026

Axogen (AXGN) Q3 2025 Earnings Transcript ↗

April 28, 2026

Axogen (AXGN) Q1 2025 Earnings Transcript ↗

April 28, 2026

Axogen, Inc. Reports First Quarter 2026 Financial Results

April 28, 2026

Capricorn Fund Makes a Huge Bet on Nerve Repair With 687,000 Share Axogen (AXGN) Investment Worth $22.4 Million ↗

April 26, 2026

Axogen (AXGN) Q2 2025 Earnings Transcript ↗

April 22, 2026

Axogen, Inc. to Report First Quarter 2026 Financial Results on April 28, 2026

April 14, 2026

Axogen Insider Sale of 5,221 Shares Follows 20% Revenue Growth in 2025. Here's What to Know ↗

March 24, 2026